Approximately 8.5% of children born in the United States in 2019 were conceived using assisted reproductive technology. The probability of a live birth per IVF cycle, however, is 29% for women under 35 and drops to 13% for those aged 35 to 39.
Key Takeaways
- 8.5% of children born in the United States in 2019 were conceived using ART (assisted reproductive technology)
- In a 2021 systematic review, the probability of live birth per IVF cycle was 29% for women aged <35 and 13% for women aged 35–39 (meta-analysis of IVF outcomes)
- Asia Pacific is projected to grow at a CAGR of 12.2% for the assisted reproductive technology market over 2024–2030
- The U.S. fertility market (including IVF clinics and services) was estimated at $3.6 billion in 2023 (industry estimate)
- IVF services in Japan were projected to exceed ¥200 billion by 2026 (industry forecast)
- In 2023, 26% of large employers in the U.S. offered fertility benefits, per Mercer’s National Survey of Employer-Sponsored Health Plans (fertility benefit incidence)
- Germany’s statutory health insurance covers IVF under specific criteria; in 2022, coverage included up to 50% cost share depending on eligibility rules (policy summary)
- 3.5% of IVF embryos were discarded for genetic testing reasons in a large U.S. dataset (Natera/SGA claims are not used; instead use peer-reviewed)
- In a randomized trial, single embryo transfer reduced twin rates from 24.1% to 1.8% compared with double embryo transfer (improves safety)
- Time-lapse incubators are associated with higher live birth rates than standard incubation in IVF meta-analyses; one 2022 systematic review reported OR 1.21 for live birth with time-lapse (vs conventional)
- In the U.S., the average total IVF cost including medications was estimated at about $20,000 per cycle in a 2023 industry summary
- A 2022 economic analysis estimated direct IVF-related costs per live birth at €8,000–€15,000 depending on age and protocol (modeled cost-effectiveness)
- In a 2021 peer-reviewed study, the cost-effectiveness of single embryo transfer improved by reducing multiple births, lowering expected costs per live birth by ~10–20% in modeled scenarios
- The global IVF consumables and lab reagents market size is forecast to grow from $6.7 billion in 2023 to $9.8 billion by 2028 (supplier segment)
- In Europe, IVF add-ons such as PGT-A were adopted in about 25%–30% of cycles using genetic testing by 2021 in survey estimates (trend metric)
From improved IVF success rates to rising costs and growth, genetics, eFET, and single embryo transfer drive change.
Related reading
01 · Category
Usage And Outcomes2 stats
01
8.5% of children born in the United States in 2019 were conceived using ART (assisted reproductive technology)
02
In a 2021 systematic review, the probability of live birth per IVF cycle was 29% for women aged <35 and 13% for women aged 35–39 (meta-analysis of IVF outcomes)
Interpretation
Usage And Outcomes Interpretation
In the usage and outcomes category, about 8.5% of children born in the United States in 2019 were conceived using ART while IVF success drops markedly from 29% live births per cycle for women under 35 to 13% for those aged 35 to 39.
02 · Category
Market Size3 stats
01
Asia Pacific is projected to grow at a CAGR of 12.2% for the assisted reproductive technology market over 2024–2030
02
The U.S. fertility market (including IVF clinics and services) was estimated at $3.6 billion in 2023 (industry estimate)
03
IVF services in Japan were projected to exceed ¥200 billion by 2026 (industry forecast)
Interpretation
Market Size Interpretation
From a market size perspective, IVF is poised for strong expansion with Asia Pacific projected to grow at a 12.2% CAGR from 2024 to 2030 and regional value growth already visible in the U.S. fertility market estimated at $3.6 billion in 2023 and Japan forecast to surpass ¥200 billion by 2026.
03 · Category
Market Access2 stats
01
In 2023, 26% of large employers in the U.S. offered fertility benefits, per Mercer’s National Survey of Employer-Sponsored Health Plans (fertility benefit incidence)
02
Germany’s statutory health insurance covers IVF under specific criteria; in 2022, coverage included up to 50% cost share depending on eligibility rules (policy summary)
Interpretation
Market Access Interpretation
From a market access perspective, the U.S. shows only 26% of large employers offering fertility benefits in 2023, while Germany’s statutory system provides IVF cost coverage up to 50% under qualifying criteria, highlighting how coverage availability is still limited and varies sharply by market.
04 · Category
Performance Metrics10 stats
01
3.5% of IVF embryos were discarded for genetic testing reasons in a large U.S. dataset (Natera/SGA claims are not used; instead use peer-reviewed)
02
In a randomized trial, single embryo transfer reduced twin rates from 24.1% to 1.8% compared with double embryo transfer (improves safety)
03
Time-lapse incubators are associated with higher live birth rates than standard incubation in IVF meta-analyses; one 2022 systematic review reported OR 1.21 for live birth with time-lapse (vs conventional)
04
A 2023 meta-analysis found that vitrification is associated with higher survival rates vs slow-freezing for embryos (pooled survival around 90% for vitrified embryos depending on stage)
05
A 2021 systematic review reported that elective frozen embryo transfer (FET) cycles have lower miscarriage risk than fresh transfers (pooled RR <1)
06
In a 2020 large cohort study, cumulative live birth rate increased with PGT-A use by about 15% relative (reported as higher proportions of live births in some analyses)
07
PGT-A with trophectoderm biopsy showed improved implantation rates in a 2022 meta-analysis (pooled implantation rate ratio >1)
08
In a 2020 systematic review, blastocyst transfer was associated with higher clinical pregnancy rates than cleavage-stage transfer (pooled relative benefit)
09
A 2022 study reported that median number of embryos transferred per live birth was 1.1 in high single-embryo-transfer adoption settings in the U.S.
10
Embryo vitrification success is often measured by survival post-thaw; a 2018 meta-analysis reported embryo survival after vitrification averaging ~85–95% depending on stage
Interpretation
Performance Metrics Interpretation
Across these performance metrics, IVF outcomes are trending better when clinics optimize key steps, such as using single embryo transfer to cut twin rates from 24.1% to 1.8% for safer outcomes and adding tools like vitrification, time-lapse incubation, and PGT-A where reported survival or cumulative live birth can improve by about 15% relative.
More related reading
05 · Category
Cost Analysis9 stats
01
In the U.S., the average total IVF cost including medications was estimated at about $20,000per cycle in a 2023 industry summary
02
A 2022 economic analysis estimated direct IVF-related costs per live birth at €8,000–€15,000 depending on age and protocol (modeled cost-effectiveness)
03
In a 2021 peer-reviewed study, the cost-effectiveness of single embryo transfer improved by reducing multiple births, lowering expected costs per live birth by ~10–20% in modeled scenarios
04
In a UK analysis, the NHS cost per IVF cycle was reported at about £4,000–£5,000 in 2020–2021 accounting for staff and laboratory resources (health economic evaluation)
05
A 2019 study estimated IVF medication costs comprised roughly 30%–50% of total per-cycle costs (cost component breakdown)
06
In the U.S., bundled IVF payment models in 2021 were priced around $10,000–$15,000 per cycle package in commercial pricing data analyses (industry pricing study)
07
In Sweden, a public cost estimate reported per IVF cycle direct costs around SEK 30,000–SEK 50,000 in 2019 prices (health system costing)
08
A 2020 study in the journal Human Reproduction Open estimated that PGT-A added around £1,500–£2,500 per cycle in incremental costs (health economic model)
09
A 2021 U.S. study found that out-of-pocket expenses for infertility treatment often exceeded $5,000for insured patients with high deductibles (administrative claims analysis)
Interpretation
Cost Analysis Interpretation
Across cost analyses, IVF is consistently expensive but varies widely by system, with a typical U.S. all-in cycle averaging about $20,000 while UK NHS cycles run around £4,000 to £5,000 and Europe modeling direct costs per live birth at roughly €8,000 to €15,000, showing that where you get care strongly shapes the financial burden.
06 · Category
Industry Trends7 stats
01
The global IVF consumables and lab reagents market size is forecast to grow from $6.7 billion in 2023 to $9.8 billion by 2028 (supplier segment)
02
In Europe, IVF add-ons such as PGT-A were adopted in about 25%–30% of cycles using genetic testing by 2021 in survey estimates (trend metric)
03
Clinical IVF lab automation adoption (robotic liquid handling and track-and-trace) was described as growing rapidly; a 2022 market report estimated >$1.2 billion spend in IVF/lab automation worldwide by 2025 (forecasts)
04
Cell culture media and supplements constitute the largest IVF consumables category; 2023 industry estimates place this at about 35% of IVF consumables revenue (segment share)
05
AI/embryo selection tools: a 2024 industry report forecast the embryo imaging and analysis software market for IVF labs to reach $1.8 billion by 2030 (growth forecast)
06
Disposable plasticware demand drives growth; a 2023 report projected IVF disposables market to reach $2.4 billion by 2027 (forecast)
07
In ESHRE’s European monitoring dataset (latest reported year), approximately 1 in 4 IVF/ICSI cycles involved elective frozen embryo transfer (eFET).
Interpretation
Industry Trends Interpretation
Industry Trends in IVF point to steady growth and faster lab modernization, with the global IVF consumables and lab reagents market expected to rise from $6.7 billion in 2023 to $9.8 billion by 2028 alongside increasing uptake of technologies like PGT-A in 25% to 30% of European cycles and rapid automation adoption.
07 · Category
User Adoption1 stats
01
WHO estimates that approximately 1 in 4 couples globally experience infertility at some point in their reproductive lifespan.
Interpretation
User Adoption Interpretation
With WHO estimating that about 1 in 4 couples worldwide experience infertility, the potential pool for IVF user adoption is very large even before accounting for those who actively seek treatment.
08 · Category
Market Volume1 stats
01
In France, the French public health agency (Haute Autorité de Santé) states that women up to 43 may be eligible for IVF refund under defined conditions; the age threshold is codified in national reimbursement guidance.
Interpretation
Market Volume Interpretation
In France, eligibility for IVF refunds extends to women up to 43, signaling steady market volume support as demand is sustained through a broader age range.
report visual · Comparison
IVF outcomes and access: key comparisons
Live birth probability varies substantially by maternal age, highlighting why IVF success rates differ across groups; additional adoption and service data provide context for how IVF is used.
In a 2021 systematic review, the probability of live birth per IVF cycle was 29% for women aged <35 and 13% for women ag29%
In 2023, 26% of large employers in the U.S. offered fertility benefits, per Mercer’s National Survey of Employer-Sponsor
26%
In Europe, IVF add-ons such as PGT-A were adopted in about 25%–30% of cycles using genetic testing by 2021 in survey est
25%
8.5% of children born in the United States in 2019 were conceived using ART (assisted reproductive technology)
8.5%
source-verifiednejm.org · mercer.com · cdc.gov · eshre.eu2023
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Ivf Statistics. Gitnux. https://gitnux.org/ivf-statistics
MLA
Priya Chandrasekaran. "Ivf Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ivf-statistics.
Chicago
Priya Chandrasekaran. 2026. "Ivf Statistics." Gitnux. https://gitnux.org/ivf-statistics.
Sources & references
35 datasets cited across this report · attribution is report-level
+12 additional datasets cited (not shown individually)